Lumakras
(Sotorasib)ApprovedSmall molecule
AmgenSotorasib is used to treat a specific type of lung cancer (non-small cell lung cancer) in patients whose cancer cells have a particular genetic mutation called KRAS G12C. It works by blocking the abnormal protein that causes these cancer cells to grow.[2] Lumakras is currently approved and in use across 15 indications[4].[1]
Lumakras is one of 399 small molecule programs targeting Erectile Dysfunction. It is currently in Approved.
15
Indications
47
Total Trials
25
Active Trials
398
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
6
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 15 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Lumakras
AmgenApproved
Tecentriq
RochePreclinical
MS Contin
Merck & Co.Preclinical
Zolymbus
AbbViePreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Effexor
WWyeth-Lederle Vaccines
Preclinical
Chantix
PPrism Pharmaceuticals
Preclinical
Zoladex
Luye Pharma Group Ltd.Preclinical
Neoadjuvant Treatment
SShanghai Zhongshan Hospital
Preclinical
Recombinant Human Endostatin
PPeking University Third Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer10 trials
Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer
Recruiting·—·Phase 1·NCT06249282·15 enrolled
Show 7 more trials
Tics3 trials
Advanced NSCLC3 trials
Patients With Advanced Solid Tumors2 trials
26 more indications
Metastatic Colorectal Cancer2 trials
NSCLC1 trial
Thoracic Tumors1 trial
Hepatic Impairment1 trial
Clinical Trial1 trial
Locally Advanced or Metastatic NSCLC1 trial
Pancreatic Adenocarcinoma1 trial
Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma
Not yet recruiting·SSpanish Cooperative Group for the Treatment of Digestive Tumours (TTD)·Phase 2·NCT06892054·15 enrolled
KRAS P.G12C1 trial
Chemoradiotherapy1 trial
Sarcoma1 trial
Solid Tumor Cancers1 trial
Pancreas Cancer1 trial
Colorectal Cancer1 trial
Second-line Treatment1 trial
Lung Cancer1 trial
Erectile Dysfunction1 trial
Statin1 trial
Solid Tumor Malignancies1 trial
Advanced Malignant Solid Neoplasm1 trial
Solid Tumor1 trial
Regulatory
FDA Approval Timeline[5]
May 28, 2021
LUMAKRAS
NDA NDA214665
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Lumakras drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Sotorasib. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]